Lv6
2820 积分 2021-09-18 加入
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC
7小时前
待确认
FOLFIRINOX vs. Gemcitabine Nab-Paclitaxel in Pancreatic Cancer: A Real-World Single-Center Analysis of Efficacy and Safety
12天前
已完结
Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial
13天前
已完结
BCLC strategy for prognosis prediction and treatment recommendations: The 2025 update
20天前
已完结
Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study
25天前
已完结
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study
1个月前
已完结
Efficacy and safety of DEB-TACE combined with HAIC and donafenib in the treatment of unresectable hepatocellular carcinoma: a dual-center retrospective study
1个月前
已完结
Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma The DIAMOND Randomized Clinical Trial
1个月前
已完结
Clinical outcomes of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and anti-PD-1 immunotherapy for unresectable intrahepatic cholangiocarcinoma
1个月前
已完结
Lenvatinib combined with PD-1 inhibitor plus Gemox chemotherapy versus plus HAIC for advanced biliary tract cancer
1个月前
已完结
皖公网安备34019202002308
